SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001193125-21-229354
Filing Date
2021-07-29
Accepted
2021-07-29 17:03:14
Documents
6

Document Format Files

Seq Description Document Type Size
1 DEFM14A d182848ddefm14a.htm DEFM14A 4176373
2 GRAPHIC g182848g04x86.jpg GRAPHIC 23207
3 GRAPHIC g182848g21r80.jpg GRAPHIC 394785
4 GRAPHIC g182848g42h26.jpg GRAPHIC 36859
5 GRAPHIC g182848g80q30.jpg GRAPHIC 84971
6 GRAPHIC g182848g84t69.jpg GRAPHIC 300212
  Complete submission text file 0001193125-21-229354.txt   5329488
Mailing Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601
Business Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601 844-445-5704
XERIS PHARMACEUTICALS INC (Filer) CIK: 0001346302 (see all company filings)

IRS No.: 203352427 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 001-38536 | Film No.: 211128383
SIC: 2834 Pharmaceutical Preparations